Stay updated on Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial

Sign up to get notified when there's something new on the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    A banner about NIH website terminology updates and the transition from “Artificial Intelligence” to “Super Intelligence” is no longer displayed.
    Difference
    1%
    Check dated 2026-11-09T13:50:41.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.2 to v3.8.0. The study page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-02T15:49:59.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    A site-wide banner announces an NIH terminology transition, saying that “Super Intelligence” will replace “Artificial Intelligence” in federal agency content under an executive order.
    Difference
    1%
    Check dated 2026-10-26T15:13:19.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    The footer revision number changes from v3.7.1 to v3.7.2 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-19T14:47:43.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1; the page still displays a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-12T15:00:18.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The study record area displays a 403 Forbidden message instead of study information, with a Home link.
    Difference
    0.5%
    Check dated 2026-10-05T16:53:34.000Z thumbnail image

Stay in the know with updates to Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page.